Results 121 to 130 of about 1,192,795 (361)

Light Therapy Alleviates Addiction‐Related Symptoms and Reshapes Habenula and Midbrain Pathways

open access: yesAdvanced Science, EarlyView.
This study investigates light therapy for treating Internet Gaming Disorder (IGD). Functional MRI (fMRI) data reveal that light therapy enhances brain connectivity, particularly between the habenula and the medial orbitofrontal cortex (mOFC). These changes are associated with reduced withdrawal symptoms and addiction severity, highlighting the ...
Jinhui Li   +10 more
wiley   +1 more source

Placebo: een ingewikkeld fenomeen

open access: yesNeuropraxis, 2016
Er heerst veel verwarring over het woord ‘placebo’ in de wetenschappelijke wereld. Dit lijkt vooral veroorzaakt te worden door de uiteenlopende betekenissen die wetenschappers aan dit woord toekennen, bijvoorbeeld een klinische onderzoeker of een neurowetenschapper. Bij het testen van geneesmiddelen willen onderzoekers weten of de therapie beter is dan
Olivier, Jocelien, Olivier, Berend
openaire   +2 more sources

Esketamine/Ketamine: Dual‐Action Mechanisms and Clinical Prospects beyond Anesthesia in Psychiatry, Immunology, and Oncology

open access: yesAdvanced Science, EarlyView.
Esketamine and ketamine are widely used for perioperative analgesia and anesthesia. Despite their established roles in analgesia, sedation, and anesthesia, as well as emerging antidepressant, anti‐tumor, and anti‐inflammatory effects, their clinical use is limited due to side effects and addiction potential.
Yinxin Wang   +7 more
wiley   +1 more source

Buspirone for early satiety and symptoms of gastroparesis: A multi‐centre, randomised, placebo‐controlled, double‐masked trial ( BESST ) [PDF]

open access: bronze, 2023
Henry P. Parkman   +17 more
openalex   +1 more source

Integrin β3 Orchestrates Hepatic Steatosis via a Novel CD36‐Dependent Lipid Uptake Complex

open access: yesAdvanced Science, EarlyView.
In MASH, ITGB3 recruits LYN and drives its ubiquitin‐proteasomal degradation via phosphorylation. This relieves DHHC5 inhibition, enabling ITGB3/DHHC5/CD36 complex assembly to enhance CD36 palmitoylation and fatty acid uptake, thereby exacerbating disease. Targeting ITGB3 blocks this pathogenic axis and ameliorates MASH.
Ying Zhang   +13 more
wiley   +1 more source

Racial Differences in the Effect of Granulocyte Macrophage Colony-Stimulating Factor on Improved Walking Distance in Peripheral Artery Disease: The PROPEL Randomized Clinical Trial. [PDF]

open access: yes, 2019
Background The effects of race on response to medical therapy in people with peripheral artery disease ( PAD ) are unknown. Methods and Results In the PROPEL (Progenitor Cell Release Plus Exercise to Improve Functional Performance in PAD) Trial, PAD ...
Criqui, Michael H   +11 more
core   +1 more source

CD147/Basigin: From Integrative Molecular Hub to Translational Therapeutic Target

open access: yesAdvanced Science, EarlyView.
This review conceptualizes CD147 as a fundamental “Energy‐Structure Coupler,” physically bridging metabolic flux (via MCTs) with morphogenetic plasticity (via integrins/MMPs) to drive cancer, infection, and autoimmunity. Addressing the “specificity paradox” that limits current translation, the authors chart a strategic roadmap—spanning logic‐gated ...
Xiang‐Min Yang   +2 more
wiley   +1 more source

Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. [PDF]

open access: yes, 2019
PurposeIn the initial PALOMA-2 (NCT01740427) analysis with median follow-up of 23 months, palbociclib plus letrozole significantly prolonged progression-free survival (PFS) in women with estrogen receptor-positive (ER+)/human epidermal growth factor ...
Bartlett, C Huang   +14 more
core  

Home - About - Disclaimer - Privacy